Gubra

Regulatory press release2026-07-06 09:00

Share repurchase for employee incentive programs

Gubra

Regulatory press release2026-06-08 15:09

Gubra capital increase in connection with exercise of warrants

Gubra

Research2026-05-13 10:45 by

Michael Friis, Victor Skriver

Gubra (One-pager): A clinically pivotal quarter, with two obesity assets advancing toward Phase 2

We have updated our One-pager investment case on Gubra to reflect the Q1 2026 trading statement, the revised CRO guidance, and the clinical newsflow across the pipeline. The quarter has incrementally strengthened the D&P-driven equity value case, while the CRO downgrade has only a limited impact on our valuation framework given the segment's modest share of total enterprise value.

Gubra

Regulatory press release2026-05-12 16:41

Gubra initiates employee share matching program

Gubra

Analyst Comment2026-04-28 15:27 by

Michael Friis

Gubra – Boehringer Ingelheim's Triple Agonist BI 3034701 to Enter Phase 2 in Mid-2026

Gubra today announced that its partner Boehringer Ingelheim plans to initiate Phase 2 development of BI 3034701 in mid-2026. BI 3034701 is a potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity, originating from Gubra's peptide discovery platform. The advancement provides further validation of Gubra's platform capabilities - particularly its ability to engineer differentiated, first-in-class peptide candidates within obesity that attract continued development investment from top-tier pharma partners.

Gubra